Jefferies reiterates Hold on Mineralys stock amid M&A speculation

Jefferies reiterated a Hold rating on Mineralys Therapeutics with a $30 price target, below the current $31.84 share price, while flagging acquisition optionality during FDA review of lorundrostat. The company also reported a Q1 2026 EPS loss of $0.47, better than the $0.81 estimate, and its NDA has been accepted by the FDA. Overall, the article is balanced by strong clinical/regulatory progress and takeover speculation, offset by valuation concerns and the lack of expected profitability this year.

Analysis

MLYS is trading like an approval-plus-commercialization story, but the market may be underpricing the much higher variance around the first 90 days after label clarity. For a small-cap asset with a single-product setup, the real inflection is not just FDA action; it is whether the company can convert a clean label into credible payer access and field-force execution before any acquisition premium gets priced away. If launch data are merely adequate, the downside can be fast because the stock has already de-risked a lot of the binary approval event.

The competitive dynamic is more interesting than a simple M&A angle. A larger acquirer would likely wait for evidence that lorundrostat can defend share versus AZN’s franchise economics, which means the strongest buyers are probably companies with existing hypertension infrastructure that can bolt on the asset cheaply. That creates a second-order effect: if MLYS builds even a modest sales organization, it raises the hurdle for a strategic bid by proving the asset can be commercialized independently, but it also increases burn and narrows the window for a cash-rich acquirer to pay up before dilution concerns return.

The most actionable read is that the stock is now in the danger zone where good news may not drive much more upside, while any commercial misstep could re-rate it sharply lower. The market appears to be valuing optionality on either takeout or clean launch, yet the median outcome in this setup is often a long period of drift until first prescription data, formulary wins, and physician adoption are visible. In that sense, the risk/reward is no longer about approval probability; it is about how quickly the company can convert regulatory success into a defensible revenue slope.

The contrarian miss is that acquisition odds during review do not automatically translate into value creation for holders at this price. A buyer will likely haircut the asset for launch risk, competitive intensity, and the need for commercial build-out, so paying above the current tape before label and launch proof may be structurally unattractive. If the company needs to hire out a full field team, the market should expect operating leverage to stay negative longer than the headline pipeline excitement suggests.

Key Decisions for Investors

• Do not chase MLYS here; wait for either a post-label pullback or first commercial readout. Risk/reward is asymmetric only if the stock revisits the low-$20s on any launch disappointment, where upside to a strategic bid could re-open.
• For event-driven accounts, consider a small long-dated call spread in MLYS into the FDA decision window rather than spot equity. This limits downside if the market fades the takeout narrative while preserving upside to an approval-driven squeeze.
• Pair trade: long AZN / short MLYS into the next 1-3 months if you expect the market to overpay for MLYS optionality. The cleaner, scaled commercial platform is the lower-volatility way to express hypertension exposure.
• If owning MLYS, reduce size after approval and before the first launch/commercial metrics. That is typically the period when acquisition speculation peaks while fundamentals remain unproven.
• Watch for insider or hiring signals over the next 4-8 weeks; if field-force expansion accelerates, treat that as a signal to trim because it raises execution risk and lowers the probability of a near-term bid.